Keenova Reports Successful Phase 3 Trial for Plantar Fibromatosis Drug

Keenova Therapeutics has announced positive outcomes from its Phase 3 clinical trial for XIAFLEX® in treating plantar fibromatosis. The study achieved its primary goal, showing significant pain reduction compared to a placebo. The drug's safety profile was consistent with previous findings, with mostly mild to moderate side effects, and the company plans to seek FDA approval later this year.